Anebulo Pharmaceuticals (ANEB) Competitors

Anebulo Pharmaceuticals (NASDAQ:ANEB) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation, community ranking and profitability.

Do insiders & institutionals have more ownership in ANEB or FDMT?

28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Comparatively, 9.6% of 4D Molecular Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in ANEB or FDMT?

4D Molecular Therapeutics received 49 more outperform votes than Anebulo Pharmaceuticals when rated by MarketBeat users. However, 90.91% of users gave Anebulo Pharmaceuticals an outperform vote while only 64.13% of users gave 4D Molecular Therapeutics an outperform vote.

Company	Underperform	Outperform
Anebulo Pharmaceuticals	Outperform Votes 10 90.91%	Underperform Votes 1 9.09%
4D Molecular Therapeutics	Outperform Votes 59 64.13%	Underperform Votes 33 35.87%

Do analysts rate ANEB or FDMT?

Anebulo Pharmaceuticals presently has a consensus target price of $5.50, suggesting a potential upside of 333.07%. 4D Molecular Therapeutics has a consensus target price of $29.56, suggesting a potential upside of 556.79%. Given 4D Molecular Therapeutics' higher probable upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
4D Molecular Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Does the media favor ANEB or FDMT?

In the previous week, 4D Molecular Therapeutics had 5 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 6 mentions for 4D Molecular Therapeutics and 1 mentions for Anebulo Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 1.89 beat 4D Molecular Therapeutics' score of 1.54 indicating that Anebulo Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Anebulo Pharmaceuticals	Very Positive
4D Molecular Therapeutics	Very Positive

Which has more volatility & risk, ANEB or FDMT?

Anebulo Pharmaceuticals has a beta of -1.15, suggesting that its share price is 215% less volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.84, suggesting that its share price is 184% more volatile than the S&P 500.

Is ANEB or FDMT more profitable?

4D Molecular Therapeutics' return on equity of -28.00% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-119.54%	-108.08%
4D Molecular Therapeutics	N/A	-28.00%	-26.16%

Which has stronger earnings and valuation, ANEB or FDMT?

Anebulo Pharmaceuticals has higher earnings, but lower revenue than 4D Molecular Therapeutics. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.20M	-$0.26	-4.88
4D Molecular Therapeutics	$23K	9,063.59	-$100.84M	-$3.18	-1.42

Summary

4D Molecular Therapeutics beats Anebulo Pharmaceuticals on 10 of the 16 factors compared between the two stocks.